Table 3.
Characteristics of the 76 multiple myeloma (MM) cases.
| Variable | Number of MM Patients (%) |
|---|---|
| Gender | |
| Male | 44 (57.9%) |
| Female | 32 (42.1%) |
| Myeloma type | |
| IgG | 44 (57.9%) |
| IgA | 17 (22.4%) |
| IgD | 2 (2.6%) |
| Light chain | 10 (13.2%) |
| Non-secretory | 2 (2.6%) |
| Missing data | 1 (1.3%) |
| ISS 1 stage | |
| I | 15 (19.7%) |
| II | 25 (32.9%) |
| III | 34 (44.8%) |
| Missing data | 2 (2.6%) |
| R-ISS 2 stage | |
| I | 11 (14.5%) |
| II | 40 (52.6%) |
| III | 18 (23.7%) |
| Missing data | 7 (9.2%) |
| Bone disease | |
| No | 22 (28.9%) |
| Yes | 50 (65.8%) |
| Missing data | 4 (5.3%) |
| WBLDCT 3 osteolysis | |
| No | 18 (23.7%) |
| Yes | 38 (50.0%) |
| Missing data | 20 (26.3%) |
| SREs 4 (38 MM patients) | |
| No | 18 (47.4%) |
| Yes | 20 (52.6%) |
1 International Staging System. 2 Revised International Staging System. 3 Whole-body low-dose computed tomography. 4 Skeletal-related events; only patients with osteolysis are assessed for the presence of SREs.